See more : CIFI Ever Sunshine Services Group Limited (1995.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Biocept, Inc. (BIOC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Biocept, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Delek Group Ltd. (DLEKG.TA) Income Statement Analysis – Financial Results
- NAOS Emerging Opportunities Company Limited (NCC.AX) Income Statement Analysis – Financial Results
- LVMH Moët Hennessy – Louis Vuitton, Société Européenne (MC.SW) Income Statement Analysis – Financial Results
- NewtekOne, Inc. 8.00% Fixed Rate Senior Notes due 2028 (NEWTI) Income Statement Analysis – Financial Results
- Black Hawk Acquisition Corporation Class A Ordinary Shares (BKHA) Income Statement Analysis – Financial Results
Biocept, Inc. (BIOC)
About Biocept, Inc.
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians; clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations; and RT-PCR testing services for COVID-19. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.86M | 61.25M | 27.46M | 5.53M | 3.25M | 5.07M | 3.22M | 609.91K | 133.42K | 134.25K | 109.29K | 1.05K |
| Cost of Revenue | 28.44M | 37.76M | 21.34M | 10.98M | 10.05M | 9.35M | 6.92M | 4.60M | 2.17M | 2.33M | 1.20M | 17.32K |
| Gross Profit | -2.58M | 23.49M | 6.12M | -5.45M | -6.80M | -4.28M | -3.70M | -3.99M | -2.04M | -2.20M | -1.09M | -16.27K |
| Gross Profit Ratio | -9.99% | 38.34% | 22.30% | -98.56% | -209.26% | -84.37% | -114.70% | -653.58% | -1,526.91% | -1,635.56% | -999.56% | -1,546.58% |
| Research & Development | 6.16M | 4.96M | 5.22M | 4.70M | 4.47M | 3.36M | 2.71M | 2.86M | 4.50M | 3.09M | 6.56M | 8.85M |
| General & Administrative | 16.11M | 12.61M | 9.97M | 6.97M | 7.07M | 7.19M | 6.56M | 5.69M | 5.20M | 2.51M | 2.06M | 2.73M |
| Selling & Marketing | 7.13M | 8.32M | 6.40M | 5.94M | 5.91M | 6.34M | 5.05M | 3.88M | 2.14M | 148.90K | 785.32K | 672.93K |
| SG&A | 23.24M | 20.93M | 16.37M | 12.91M | 12.99M | 13.53M | 11.61M | 9.57M | 7.34M | 2.66M | 2.85M | 3.40M |
| Other Expenses | 0.00 | 0.00 | 0.00 | -1.83M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 29.40M | 25.89M | 21.59M | 17.61M | 17.46M | 16.90M | 14.33M | 12.42M | 11.84M | 5.75M | 9.41M | 12.25M |
| Cost & Expenses | 57.84M | 63.66M | 42.93M | 28.59M | 27.51M | 26.24M | 21.25M | 17.02M | 14.01M | 8.08M | 10.61M | 12.27M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 316.00K | 290.00K | 2.34M | 2.08M | 310.98K | 0.00 | 0.00 | 0.00 | 0.00 | 2.07M | 0.00 | 0.00 |
| Depreciation & Amortization | 1.66M | 2.64M | 1.00M | 773.31K | 800.91K | 575.72K | 322.03K | 261.41K | 251.20K | 266.55K | 365.57K | 369.31K |
| EBITDA | -30.33M | -2.41M | -15.47M | -23.06M | -24.26M | -21.17M | -18.03M | -16.41M | -13.87M | -7.68M | -10.57M | -12.24M |
| EBITDA Ratio | -117.29% | -3.93% | -56.33% | -417.05% | -746.35% | -417.76% | -559.25% | -2,690.70% | -10,399.07% | -5,719.30% | -9,671.01% | -1,163,859.41% |
| Operating Income | -31.98M | -2.41M | -15.47M | -23.06M | -24.26M | -21.17M | -18.03M | -16.41M | -13.87M | -7.94M | -10.50M | -12.27M |
| Operating Income Ratio | -123.69% | -3.93% | -56.33% | -417.05% | -746.35% | -417.76% | -559.25% | -2,690.70% | -10,399.07% | -5,917.86% | -9,610.37% | -1,166,444.49% |
| Total Other Income/Expenses | -229.00K | -290.00K | -2.34M | -2.08M | -310.98K | -431.41K | -372.23K | -537.12K | -1.99M | -1.29M | -1.76M | -1.36M |
| Income Before Tax | -32.21M | -2.70M | -17.81M | -25.14M | -24.57M | -21.61M | -18.40M | -16.95M | -15.86M | -9.23M | -12.26M | -13.63M |
| Income Before Tax Ratio | -124.57% | -4.41% | -64.84% | -454.69% | -755.92% | -426.27% | -570.79% | -2,778.76% | -11,891.12% | -6,877.26% | -11,216.80% | -1,295,483.46% |
| Income Tax Expense | -125.00K | 125.00K | -764.58K | -523.33K | 1.89K | 7.62K | 2.05K | 1.61K | 1.51K | 800.00 | 800.00 | 800.00 |
| Net Income | -32.09M | -2.82M | -17.04M | -24.61M | -24.57M | -21.61M | -18.40M | -16.95M | -15.87M | -9.23M | -12.26M | -13.63M |
| Net Income Ratio | -124.09% | -4.61% | -62.06% | -445.23% | -755.98% | -426.42% | -570.86% | -2,779.03% | -11,892.25% | -6,877.86% | -11,217.53% | -1,295,559.51% |
| EPS | -56.78 | -5.73 | -43.16 | -357.54 | -2.63K | -7.07K | -17.29K | -23.28K | -96.74K | -55.29K | -73.41K | -81.61K |
| EPS Diluted | -56.78 | -5.73 | -43.16 | -357.41 | -2.63K | -7.07K | -17.29K | -23.28K | -96.74K | -55.29K | -73.41K | -81.61K |
| Weighted Avg Shares Out | 565.13K | 492.53K | 394.84K | 68.85K | 9.33K | 3.06K | 1.06K | 728.00 | 164.00 | 167.00 | 167.00 | 167.00 |
| Weighted Avg Shares Out (Dil) | 565.13K | 492.53K | 394.84K | 68.87K | 9.33K | 3.06K | 1.06K | 728.00 | 164.00 | 167.00 | 167.00 | 167.00 |
Biocept appoints Antonino Morales as president and chief executive officer
Biocept Names Antonino Morales as President and Chief Executive Officer
Biocept to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 20, 2023
Biocept says poster presentation at ASCO highlights impressive performance of CNSide assay in detecting leptomeningeal metastases
Scientific Poster Presented at the 2023 ASCO Annual Meeting Highlights Performance of Biocept's CNSide™ Versus Cytology
Why Is Biocept (BIOC) Stock Down 42% Today?
Biocept Announces Pricing of $5.0 Million Underwritten Public Offering
Biocept shares to commence trading on split-adjusted basis
Biocept Announces One-for-Thirty Reverse Stock Split
Biocept Announces One-for-Thirty Reverse Stock Split
Source: https://incomestatements.info
Category: Stock Reports